Tickborne Diseases 1.0 Test

Tickborne Diseases 1.0 TestThe Tickborne Diseases 1. 0 Test is a comprehensive diagnostic panel designed to assess exposure to Lyme disease and key tick borne co infections. Utilizing advanced immunoassay and PCR technologies, this test evaluates both immune response (IgG IgM antibodies) and direct pathogen DNA, providing clinically relevant insights into current and past infections. Comprehensive Tick Borne Infection Analysis Focused Lyme & Core Co Infection PanelEvaluates

The Tickborne Diseases 1.0 Test is a comprehensive diagnostic panel designed to assess exposure to Lyme disease and key tick-borne co-infections. Utilizing advanced immunoassay and PCR technologies, this test evaluates both immune response (IgG/IgM antibodies) and direct pathogen DNA, providing clinically relevant insights into current and past infections.

Comprehensive Tick-Borne Infection Analysis

Focused Lyme & Core Co-Infection Panel
Evaluates Borrelia (Lyme disease) across multiple species and strains, along with major co-infections including Babesia, Bartonella, Anaplasma, and Ehrlichia, delivering a targeted yet robust assessment of tick-borne disease exposure.

Dual Detection Methodology (Serology + PCR)

Combines semiquantitative IgG/IgM antibody detection with real-time PCR testing to identify both immune response and active pathogen DNA, enhancing sensitivity and clinical accuracy.

Advanced CLIA & qPCR Technology

Utilizes multiplexed chemiluminescence immunoassay (CLIA) alongside probe-based qPCR/RT-qPCR for high-throughput, precise detection of multiple pathogens within a single panel.

Actionable Clinical Insights

Results are categorized into in control, moderate, or elevated, with organism-specific breakdowns and antibody markers to support clinical interpretation and treatment planning.

Longitudinal Health Tracking

Includes comparison to prior results (when available), enabling providers to monitor disease progression, treatment response, and long-term patient outcomes.